Users can get a trial run of the neuromodulation therapy before having the Proclaim DRG system implanted.
Artificial intelligence–powered software prioritizes the assessment of computed tomography cases that may have indications of brain bleed.
News of Edwards Lifesciences' CE mark for Sapien 3 Ultra was dampened by Boston Scientific's preliminary injunction on the device in Germany.
The Galway, Ireland-based company is now aimed at gaining FDA approval, but Teleflex is looking to enter the U.S. market and Abbott Laboratories has leading share in the space.
The Irvine, CA-based company estimates it could get a PMA for its rechargeable sacral neuromodulation to treat urinary dysfunction and fecal dysfunction sometime in 2019.
The recall was prompted by an incident in which the top detector of a Millennium Nuclear Medical System detached and fell onto the detector below.
The spotlight will be on digital health products at the upcoming BIOMEDevice San Jose show. Hear now from one company making an impact.
FDA is alerting doctors and patients about the risk of complications when certain implanted pumps are used to deliver pain medications not approved for use with the devices.
Sweetch is using artificial intelligence to help change people’s lifestyles who are at risk for diabetes, which is a slightly different method for tackling the disease.
Precise Bio is trying to develop bio-printed eye-related tissues to treat ophthalmic diseases. The company has already transplanted a 3D-printed corneal graft in animals.
Medtronic is the undisputed leader of the drug-coated balloon space, but Philips is vying for an indication that could potentially impact the Dublin-based firm’s hold on the market.